日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial.

INO-4800 DNA疫苗对SARS-CoV-2的安全性和免疫原性:一项开放标签1期临床试验的初步报告

Tebas Pablo, Yang ShuPing, Boyer Jean D, Reuschel Emma L, Patel Ami, Christensen-Quick Aaron, Andrade Viviane M, Morrow Matthew P, Kraynyak Kimberly, Agnes Joseph, Purwar Mansi, Sylvester Albert, Pawlicki Jan, Gillespie Elisabeth, Maricic Igor, Zaidi Faraz I, Kim Kevin Y, Dia Yaya, Frase Drew, Pezzoli Patrick, Schultheis Katherine, Smith Trevor R F, Ramos Stephanie J, McMullan Trevor, Buttigieg Karen, Carroll Miles W, Ervin John, Diehl Malissa C, Blackwood Elliott, Mammen Mammen P, Lee Jessica, Dallas Michael J, Brown Ami Shah, Shea Jacqueline E, Kim J Joseph, Weiner David B, Broderick Kate E, Humeau Laurent M

One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model.

SARS-CoV-2 合成 DNA 疫苗 INO-4800 的一剂或两剂方案可在非人灵长类动物攻毒模型中预防呼吸道疾病负担

Gooch Karen E, Smith Trevor R F, Salguero Francisco J, Fotheringham Susan A, Watson Robert J, Dennis Mike J, Handley Alastair, Humphries Holly E, Longet Stephanie, Tipton Tom, Sarfas Charlotte, Sibley Laura, Slack Gillian S, Rayner Emma, Ryan Kathryn A, Schultheis Katherine, Ramos Stephanie J, White Andrew, Charlton Sue, Sharpe Sally A, Gleeson Fergus, Humeau Laurent M, Hall Yper, Broderick Kate E, Carroll Miles W